Accession Number:

ADA411919

Title:

Identification of Widely Applicable Tumor-Associated Antigens for Breast Cancer Immunotherapy

Descriptive Note:

Annual rept. 15 Sep 2001-14 Sep 2002

Corporate Author:

JOHNS HOPKINS UNIV BALTIMORE MD SCHOOLOF MEDICINE

Personal Author(s):

Report Date:

2002-10-01

Pagination or Media Count:

14.0

Abstract:

This study is the initial phase the 1st year of a feasibility study of a novel immunotherapeutic strategy for the treatment of breast cancer. The rationale is based upon recent findings that genes belonging to the pp32 family are differentially and alternatively expressed in most human breast cancers. In general, benign breast tissues express pp32, a tumor suppressor, whereas breast cancers express tumorigenic family members, including pp32r1 and pp32r2. Since pp32r1 and pp32r2 are expressed in nearly all breast cancers, but not in normal adult tissues, they may reasonably serve as targets for antigen-specific immunotherapy. The purpose of the study is to identify tumor-associated antigens TAA in pp32r1 and pp32r2, then test their suitability in vitro as immunotherapeutic targets in breast cancer. Currently, the second phase of in vivo feasibility is underway. If successful, the results may translate into eventual clinical trials of peptide vaccines or adoptive T-cell therapy. 2 tables, 1 figure

Subject Categories:

  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE